<unk>  is a tissue factor-directed antibody and microtubule inhibitor conjugate that is FDA approved for the treatment of recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include peripheral neuropathy, alopecia, epistaxis, leukocytes decreased, creatinine increased, dry eye, activated partial thromboplastin time prolonged, hemoglobin decreased, conjunctival adverse reactions, hemorrhage, fatigue, lymphocytes decreased, nausea, prothrombin international normalized ratio increased, rash, and diarrhea..
Tisotumab vedotin-tftv
Fremanezumab-vfrm
Galcanezumab-gnlm
Moxetumomab pasudotox-tdfk
Cemiplimab-rwlc
Pembrolizumab
Ado-trastuzumab emtansine
Blinatumomab